Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 6.68 USD -1.18% Market Closed
Market Cap: 173.7m USD

Wall Street
Price Targets

RNAC Price Targets Summary
Cartesian Therapeutics Inc

Wall Street analysts forecast RNAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNAC is 35.99 USD with a low forecast of 16.16 USD and a high forecast of 46.2 USD.

Lowest
Price Target
16.16 USD
142% Upside
Average
Price Target
35.99 USD
439% Upside
Highest
Price Target
46.2 USD
592% Upside
Cartesian Therapeutics Inc Competitors:
Price Targets
IVA
Inventiva SA
224% Upside
RIGL
Rigel Pharmaceuticals Inc
5% Upside
002007
Hualan Biological Engineering Inc
25% Upside
SERA
Sera Prognostics Inc
45% Upside
ASND
Ascendis Pharma A/S
30% Upside
CRSP
CRISPR Therapeutics AG
46% Upside
2480
Beijing Luzhu Biotechnology Co Ltd
34% Upside
BCYC
Bicycle Therapeutics PLC
207% Upside

Revenue
Forecast

Revenue Estimate
Cartesian Therapeutics Inc

For the last 9 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is 23%. The projected CAGR for the next 4 years is -11%.

23%
Past Growth
-11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Cartesian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Cartesian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RNAC's stock price target?
Price Target
35.99 USD

According to Wall Street analysts, the average 1-year price target for RNAC is 35.99 USD with a low forecast of 16.16 USD and a high forecast of 46.2 USD.

What is Cartesian Therapeutics Inc's Revenue forecast?
Projected CAGR
-11%

For the last 9 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is 23%. The projected CAGR for the next 4 years is -11%.

Back to Top